Trial Profile
STEM: A Multicentre Phase 2 Study of SFX-01 Treatment and Evaluation in Patients With Estrogen Receptor (ER) Positive and Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer Progressing on Either an Aromatase Inhibitor (AI) or Tamoxifen or Fulvestrant
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Sulforafan (Primary) ; Anastrozole; Aromatase inhibitors; Exemestane; Fulvestrant; Fulvestrant; Letrozole; Tamoxifen
- Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms STEM
- Sponsors Evgen Pharma
- 11 Jul 2019 Status changed from active, no longer recruiting to completed.
- 15 Mar 2019 This trial has been completed in France, according to European Clinical Trials Database.
- 26 Feb 2019 This trial has been completed in Spain, according to European Clinical Trials Database.